Ginsenosides Rg3 attenuates glucocorticoid-induced osteoporosis through regulating BMP-2/BMPR1A/Runx2 signaling pathway
Authors:
- 1 August 2016
- journal article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 256, 188-197
Abstract
No abstract availableKeywords
Funding Information
- Special Health Scientific Research Foundation of Liaoning Province (LNCCC-A03-2014)
- Science and Technology Project of Shenyang City (F16-206-9-21)
This publication has 49 references indexed in Scilit:
- Estrogen and bone health in men and womenSteroids, 2015
- 3 Tesla MRI detects deterioration in proximal femur microarchitecture and strength in long‐term glucocorticoid users compared with controlsJournal of Magnetic Resonance Imaging, 2015
- Role of dehydroepiandrosterone in management of glucocorticoid-induced secondary osteoporosis in female ratsExperimental and Toxicologic Pathology, 2012
- TGF-β and BMP Signaling in Osteoblast Differentiation and Bone FormationInternational Journal of Biological Sciences, 2012
- Bone turnover markers in the management of postmenopausal osteoporosisClinical Biochemistry, 2009
- Conversion of major ginsenoside Rb1 to 20(S)-ginsenoside Rg3 by Microbacterium sp. GS514Phytochemistry, 2008
- Glucocorticoid-induced osteoporosis: pathophysiology and therapyOsteoporosis International, 2007
- Genetic Analysis of the Roles of BMP2, BMP4, and BMP7 in Limb Patterning and SkeletogenesisPLOS Genetics, 2006
- Ginseng pharmacologyBiochemical Pharmacology, 1999
- Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion.Journal of Clinical Investigation, 1985